Figure 3
![Figure 3. Progression free survival. (A) PFS for O-DHAP and O-ICE. Median PFS for O-DHAP was 301 days (95% confidence interval [CI] 152, not estimable); median PFS for O-ICE was 288 days (95% CI 177, not estimable). (B) PFS according to saaIPI, 0 to 1 risk factors vs 2 to 3 risk factors. Median PFS for 0 to 1 risk factors was not reached (95% CI: 288, not estimable), median PFS for 2 to 3 risk factors was 177 days (95% CI 117, 264). (C) PFS according to response to first-line therapy, CR >12 months vs CR ≤ 12 months or failure to achieve remission. Median PFS for CR >12 months was not reached (95% CI 375, not estimable); median PFS for CR ≤ 12 months or failure to achieve remission was 261 days (95% CI 152, 296). O, ofatumumab.](https://ash.silverchair-cdn.com/ash/content_public/journal/blood/122/4/10.1182_blood-2012-12-472027/4/499f3.jpeg?Expires=1724242371&Signature=SGaRjEeh2R3jgoKznyY~iDceWYqc64QatR0vo7NMUA33ZBBcxvrwcaHUfIQS5UZzXcTDSbYcakmtkqXsmwiQ6IsZUORYr6NUDHDmFCC74xQaCUk-VrKX2tn8LG66GaUWOutsQC1A-6qsvfmWiAkHrgFukcEmqpVbD29LEROYVAfof9p~7UhCB~PoPsD4iUgNIIDzGr4Dgpym4Jou9OpWw9GGe8YVGfv0fCSQl0fgRE7~DVBUPMR4gR5Rey4iuyUcxthKilKeGMrDsxUeeUuANMgwu4HPBbsnmcZW~rYBqvz-9YwDgHDgU-vgQo3t1YQqZCFI~rogVSNv4IZRRYZ50Q__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Progression free survival. (A) PFS for O-DHAP and O-ICE. Median PFS for O-DHAP was 301 days (95% confidence interval [CI] 152, not estimable); median PFS for O-ICE was 288 days (95% CI 177, not estimable). (B) PFS according to saaIPI, 0 to 1 risk factors vs 2 to 3 risk factors. Median PFS for 0 to 1 risk factors was not reached (95% CI: 288, not estimable), median PFS for 2 to 3 risk factors was 177 days (95% CI 117, 264). (C) PFS according to response to first-line therapy, CR >12 months vs CR ≤ 12 months or failure to achieve remission. Median PFS for CR >12 months was not reached (95% CI 375, not estimable); median PFS for CR ≤ 12 months or failure to achieve remission was 261 days (95% CI 152, 296). O, ofatumumab.
